Abstracts tagged "Japanese"

Abstract Number: 226 • 2014 ACR/ARHP Annual Meeting
Improved Prediction of Hip Fracture Using the Health Assessment Questionnaire-Disability Index and FRAX^® in Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Study
Takefumi Furuya¹, Eisuke Inoue², Kensuke Ochi¹, Osamu Ishida³, Atsuo Taniguchi⁴, Shigeki Momohara⁴ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopedics, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: The World Health Organization Fracture Risk Assessment Tool (FRAX®) algorithm can be used to estimate 10-year probabilities of hip and major osteoporotic fractures. Previously,…
Abstract Number: 223 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study
Osamu Ishida¹, Takefumi Furuya², Eisuke Inoue³, Kensuke Ochi², Katsunori Ikari², Atsuo Taniguchi⁴, Hisashi Yamanaka² and Shigeki Momohara⁴, ¹Orthopedics, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing vertebral fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA)…
Abstract Number: 2470 • 2014 ACR/ARHP Annual Meeting
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Adalimumab (ADA) showed highly efficacious in rheumatoid arthritis (RA) in the clinical trials, although there is little evidence in daily clinical practice.The clinical usefulness…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…
Abstract Number: 174 • 2013 ACR/ARHP Annual Meeting
Genetic Association On Disease Severity In Rheumatoid Arthritis: A Validation Study In Japanese Patients
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: The disease severity of rheumatoid arthritis (RA) is objectively measured by radiographic joint destruction, which is reflective of the cumulative burden of inflammation. Recently,…
Abstract Number: 2800 • 2013 ACR/ARHP Annual Meeting
Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study – A Twelve Month Placebo Controlled, Randomized, Double Blind Study
Tsutomu Takeuchi¹, Yoshiya Tanaka², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désirée van der Heijde⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL. It inhibits osteoclast-induced bone resorption by preventing the binding of…
Abstract Number: 2322 • 2013 ACR/ARHP Annual Meeting
Post–Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis
Tsutomu Takeuchi¹, Kazuhiko Yamamoto^2,3, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Mariko Kobayashi¹⁰, Toshiharu Shoji¹⁰, Nobuyuki Miyasaka¹¹ and Takao Koike¹², ¹Department of Rheumatology, Keio University, Tokyo, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Tokyo Medical and Dental University, Tokyo, Japan, ¹²Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: Certolizumab pegol (CZP) with MTX (J-RAPID; NCT00791999) and without MTX (HIKARI; NCT00791921) has demonstrated rapid and sustained improvements in disease activity in Japanese patients…
Abstract Number: 2323 • 2013 ACR/ARHP Annual Meeting
Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Tadao Okamoto⁹, Yumiko Wada⁹, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Keio University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Nagoya, Japan, ⁶Sasebo City General Hospital, Sasebo, Japan, ⁷Tohoku University, Sendai, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹UCB Pharma, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: The therapeutic goals of treating rheumatoid arthritis (RA) are clinical, structural and functional remissions.1,2 Simultaneously achieving all three has been referred to as comprehensive…
Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Takao Koike¹, Masayoshi Harigai², Naoki Ishiguro³, Shigeko Inokuma⁴, Junnosuke Ryu⁵, Syuji Takei⁶, Tsutomu Takeuchi⁷, Y. Tanaka⁸, Masahiko Watanabe⁹ and Hisashi Yamanaka¹⁰, ¹Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Department of Allergy and Rheumatology diseases, Japanese Red Cross Medical Center, Tokyo, Japan, ⁵Nihon University School of Medicine, Tokyo, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Bristol-Myers K.K, Tokyo, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…
Abstract Number: 1216 • 2013 ACR/ARHP Annual Meeting
Risk Factors Associated With Fracture Occurrence Appear to Differ Between Distal Radius, Clinical Vertebral, and Hip Fractures in Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study
Kensuke Ochi¹, Takefumi Furuya¹, Yuki Go¹, Eisuke Inoue², Katsunori Ikari¹, Atsuo Taniguchi², Hisashi Yamanaka¹ and Shigeki Momohara², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort…
Abstract Number: 588 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Nobuyuki Miyasaka⁴, Takayuki Sumida⁵, Tsuneyo Mimori⁶, Takao Koike⁷ and Kazuhiro Endo⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ⁸Clinical Development, Zenyaku Kogyo Co., Ltd., Tokyo, Japan
Background/Purpose: B-cell depletion therapy by rituximab has been reported to be useful for treatment of lupus nephritis (LN) in many observational uncontrolled studies, however, placebo-controlled…
Abstract Number: 1957 • 2012 ACR/ARHP Annual Meeting
Prevalence and Associated Factors of Vitamin D Insufficiency and Deficiency in 4,793 Japanese Patients with Rheumatoid Arthritis
Takefumi Furuya¹, Takayuki Hosoi², Eiichi Tanaka³, Ayako Nakajima⁴, Atsuo Taniguchi⁵, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Aichi, Japan, ³Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Vitamin D (25[OH]D) insufficiency and deficiency is reported to be common in patients with rheumatoid arthritis (RA) and is associated with increased disease activity…
Abstract Number: 1312 • 2012 ACR/ARHP Annual Meeting
Clinical Response At 12 Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration
Tsutomu Takeuchi¹, Kazuhiko Yamamoto², Hisashi Yamanaka³, Naoki Ishiguro⁴, Yoshiya Tanaka⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹Keio University School of Medicine, Tokyo, Japan, ²Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁵The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁷Research Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹Sapporo medical center NTT EC, Sapporo, Japan
Background/Purpose: The majority of patients (pts) with active rheumatoid arthritis (RA) have previously been shown to respond during the first 12 weeks (wks) of certolizumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].